Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens

References

• Lin SY, Chen GY, Hu YC. Recent patents on the baculovirus systems. Recent Pat Biotehnol 2001;5:1-11
   Google Scholar
• Hitchman RB, Possee RD, King LA. Baculovirus expression systems for recombinant protein production in insect cells. Recent Pat Biotechnol 2009;3:46-54
   PubMedGoogle Scholar
• Palmberger D, Klausberger M, Berger I, et al. MultiBac turns sweet. Bioengineered 2013;4:78-83
   PubMed Web of Science ®Google Scholar
• Hu YC. Baculovirus vectors for gene therapy. Adv Virus Res 2006;68:287-320
   PubMed Web of Science ®Google Scholar
• Hu YC. Baculoviral vectors for gene delivery: a review. Curr Gene Ther 2008;8:54-65
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin CY, Chen GY, et al. Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol Adv 2011;29:618-31
   PubMed Web of Science ®Google Scholar
• Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine 2012;30:1759-66
   PubMed Web of Science ®Google Scholar
• Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines 2011;10:1063-81
   PubMed Web of Science ®Google Scholar
• Fernandes F, Teixeira AP, Carinhas N, et al. Insect cells as a production platform of complex virus-like particles. Expert Rev Vaccines 2013;12:225-36
   PubMed Web of Science ®Google Scholar
• Contreras-Gomez A, Sanchez-Miron A, Garcia-Camacho F, et al. Protein production using the baculovirus-insect cell expression system. Biotechnol Prog 2014;30:1-18
   PubMed Web of Science ®Google Scholar
• Urabe M, Ding CT, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-43
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2012;20:1831-2
   PubMed Web of Science ®Google Scholar
• Hu YC. Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol Sin 2005;26:405-16
   PubMed Web of Science ®Google Scholar
• Zeng JM, Du J, Lin JK, et al. High-efficiency transient transduction of human embryonic stem cell-derived neurons with baculoviral vectors. Mol Ther 2009;17:1585-93
   PubMed Web of Science ®Google Scholar
• Lee EX, Lam DH, Wu C, et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011;8:1515-24
   PubMed Web of Science ®Google Scholar
• Lin CY, Lin KJ, Kao CY, et al. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials 2011;32:6505-14
   PubMed Web of Science ®Google Scholar
• Lin CY, Chang YH, Lin KJ, et al. The healing of critical-sized femoral segmental bone defects in rabbits using baculovirus-engineered mesenchymal stem cells. Biomaterials 2010;31:3222-30
   PubMed Web of Science ®Google Scholar
• Bak XY, Lam DH, Yang JY, et al. Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma. Hum Gene Ther 2011;22:1365-77
   PubMed Web of Science ®Google Scholar
• Bak XY, Yang J, Wang S. Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy. Cancer Gene Ther 2010;17:721-9
   PubMed Web of Science ®Google Scholar
• Zhu H, Lau CH, Goh SL, et al. Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res 2013;41:e180
   PubMed Web of Science ®Google Scholar
• Chen GY, Pang DW, Hwang SM, et al. A graphene-based platform for induced pluripotent stem cells culture and differentiation. Biomaterials 2012;33:418-27
   PubMed Web of Science ®Google Scholar
• Sung LY, Chen CL, Lin SY, et al. Efficient gene delivery into cell lines and stem cells using baculovirus. Nat Protoc 2014;9:1882-99
   PubMed Web of Science ®Google Scholar
• Kost TA, Condreay JP, Ames RS. Baculovirus gene delivery: a flexible assay development tool. Curr Gene Ther 2010;10:168-73
   PubMed Web of Science ®Google Scholar
• Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005;23:567-75
   PubMed Web of Science ®Google Scholar
• Ho YC, Chen HC, Wang KC, et al. Highly efficient baculovirus-mediated gene transfer into rat chondrocytes. Biotechnol Bioeng 2004;88:643-51
   PubMed Web of Science ®Google Scholar
• Wang KC, Wu JC, Chung YC, et al. Baculovirus as a highly efficient gene delivery vector for the expression of hepatitis delta virus antigens in mammalian cells. Biotechnol Bioeng 2005;89:464-73
   PubMed Web of Science ®Google Scholar
• Sung LY, Lo WH, Chiu HY, et al. Modulation of chondrocyte phenotype via baculovirus-mediated growth factor expression. Biomaterials 2007;28:3437-47
   PubMed Web of Science ®Google Scholar
• Lo WH, Hwang SM, Chuang CK, et al. Development of a hybrid baculoviral vector for sustained transgene expression. Mol Ther 2009;17:658-66
   PubMed Web of Science ®Google Scholar
• Merrihew RV, Clay WC, Condreay JP, et al. Chromosomal integration of transduced recombinant baculovirus DNA in mammalian cells. J Virol 2001;75:903-9
   PubMed Web of Science ®Google Scholar
• Luo WY, Lin SY, Lo KW, et al. Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo. J Virol 2013;87:4965-73
   PubMed Web of Science ®Google Scholar
• Strauss R, Huser A, Ni S, et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol Ther 2007;15:193-202
   PubMed Web of Science ®Google Scholar
• Liu CY, Chen HZ, Chao YC. Maximizing baculovirus-mediated foreign proteins expression in mammalian cells. Curr Gene Ther 2010;10:232-41
   PubMed Web of Science ®Google Scholar
• Lesch HP, Laitinen A, Peixoto C, et al. Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther 2011;18:531-8
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu C, Zhuang J, et al. Baculovirus expression of cloned porcine arterivirus generates infectious particles in both insect and mammalian cells. J Biotechnol 2010;150:251-8
   PubMed Web of Science ®Google Scholar
• Grabherr R, Ernst W. Baculovirus for eukaryotic protein display. Curr Gene Ther 2010;10:195-200
   PubMed Web of Science ®Google Scholar
• Wang S, Balasundaram G. Potential cancer gene therapy by baculoviral transduction. Curr Gene Ther 2010;10:214-25
   PubMed Web of Science ®Google Scholar
• Luo WY, Shih YS, Hung CL, et al. Development of the hybrid Sleeping Beauty-baculovirus vector for sustained gene expression and cancer therapy. Gene Ther 2012;19:844-51
   PubMed Web of Science ®Google Scholar
• Lin CY, Lu CH, Luo WY, et al. Baculovirus as a gene delivery vector for cartilage and bone tissue engineering. Curr Gene Ther 2010;10:242-54
   PubMed Web of Science ®Google Scholar
• Liao YH, Chang YH, Sung LY, et al. Osteogenic differentiation of adipose-derived stem cells and calvarial defect repair using baculovirus-mediated co-expression of BMP-2 and miR-148b. Biomaterials 2014;35:4901-10
   PubMed Web of Science ®Google Scholar
• Lin CY, Chang YH, Li KC, et al. The use of ASCs engineered to express BMP2 or TGF-β3 within scaffold constructs to promote calvarial bone repair. Biomaterials 2013;34:9401-12
   PubMed Web of Science ®Google Scholar
• Chen HC, Sung LY, Lo WH, et al. Combination of baculovirus-mediated BMP-2 expression and rotating-shaft bioreactor culture synergistically enhances cartilage formation. Gene Ther 2008;15:309-17
   PubMed Web of Science ®Google Scholar
• Chen HC, Lee HP, Ho YC, et al. Combination of baculovirus-mediated gene transfer and rotating-shaft bioreactor for cartilage tissue engineering. Biomaterials 2006;27:3154-62
   PubMed Web of Science ®Google Scholar
• Hu YC, Yao K, Wu TY. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines 2008;7:363-71
   PubMed Web of Science ®Google Scholar
• Madhan S, Prabakaran M, Kwang J. Baculovirus as vaccine vectors. Curr Gene Ther 2010;10:201-13
   PubMed Web of Science ®Google Scholar
• Tani H, Abe T, Matsunaga TM, et al. Baculovirus vector for gene delivery and vaccine development. Future Virol 2008;3:35-43
   Web of Science ®Google Scholar
• Bayer: science for a better life. Available from: www.bayer.com
   Google Scholar
• Merck. Available from: www.merck.com
   Google Scholar
• Boehringer-ingelheim. Available from: www.boehringer-ingelheim.com/
   Google Scholar
• GSK. Available from: www.gsk.com
   Google Scholar
• Dendreon: Targeting cancer,transforming lives. Available from: www.dendreon.com
   Google Scholar
• Protein sciences corporation. Available from: www.proteinsciences.com
   Google Scholar
• Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012;7:e50852
   PubMed Web of Science ®Google Scholar
• Blanco JC, Boukhvalova MS, Pletneva LM, et al. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 2014;32:1495-500
   PubMed Web of Science ®Google Scholar
• Skoberne M, Cardin R, Lee A, et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. J Virol 2013;87:3930-42
   PubMed Web of Science ®Google Scholar
• Awasthi S, Belshe RB, Friedman HM. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. J Infect Dis 2014;210(4):571-5
   PubMed Web of Science ®Google Scholar
• Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011;85:10472-86
   PubMed Web of Science ®Google Scholar
• Awasthi S, Lubinski JM, Friedman HM. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 2009;27:6845-53
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61
   PubMed Web of Science ®Google Scholar
• Awasthi S, Balliet JW, Flynn JA, et al. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J Virol 2014;88:2000-10
   PubMed Web of Science ®Google Scholar
• Emerson SU, Purcell RH. Recombinant vaccines for hepatitis E. Trends Mol Med 2001;7:462-6
   PubMed Web of Science ®Google Scholar
• Schachner A, Marek A, Jaskulska B, et al. Recombinant FAdV-4 fiber-2 protein protects chickens against hepatitis-hydropericardium syndrome (HHS). Vaccine 2014;32:1086-92
   PubMed Web of Science ®Google Scholar
• Perez-Martin E, Gomez-Sebastian S, Argilaguet JM, et al. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae. Vaccine 2010;28:2340-9
   PubMed Web of Science ®Google Scholar
• Wang YP, Liu D, Guo LJ, et al. Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-gamma in mice. Vaccine 2013;31:833-8
   PubMed Web of Science ®Google Scholar
• Yin X, Li Z, Li J, et al. Rabies virus nucleoprotein expressed in silkworm pupae at high-levels and evaluation of immune responses in mice. J Biotechnol 2013;163:333-8
   PubMed Web of Science ®Google Scholar
• Diamyd medical. Available from: www.diamyd.com/
   Google Scholar
• Kawano M, Matsui M, Handa H. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. Expert Rev Vaccines 2013;12:199-210
   PubMed Web of Science ®Google Scholar
• Roldão A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010;9:1149-76
   PubMed Web of Science ®Google Scholar
• Kost TA, Condreay JP. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr Opin Biotechnol 1999;10:428-33
   PubMed Web of Science ®Google Scholar
• Zhang T, Xu Y, Qiao L, et al. Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 2010;28:3479-87
   PubMed Web of Science ®Google Scholar
• Senger T, Schadlich L, Gissmann L, et al. Enhanced papillomavirus-like particle production in insect cells. Virology 2009;388:344-53
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011;365:2178-87
   PubMed Web of Science ®Google Scholar
• Norwalk Vaccine Study. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00973284&Search=Search
   Google Scholar
• Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine. Available from: http://clinicaltrials.gov/ct2/results?term=NCT02038907&Search=Search
   Google Scholar
• Blazevic V, Lappalainen S, Nurminen K, et al. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011;29:8126-33
   PubMed Web of Science ®Google Scholar
• Tamminen K, Lappalainen S, Huhti L, et al. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013;8:e70409
   PubMed Web of Science ®Google Scholar
• Chen Z, Li C, Zhu Y, et al. Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein. Virus Res 2012;169:306-9
   PubMed Web of Science ®Google Scholar
• Feng H, Liang M, Wang HL, et al. Recombinant canine parvovirus-like particles express foreign epitopes in silkworm pupae. Vet Microbiol 2011;154:49-57
   PubMed Web of Science ®Google Scholar
• Feng H, Hu GQ, Wang HL, et al. Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity. PLoS One 2014;9:e79575
   PubMed Web of Science ®Google Scholar
• Kang SM, Song JM, Quan FS, et al. Influenza vaccines based on virus-like particles. Virus Res 2009;143:140-6
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85:10945-54
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 2012;8:411-14
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011;29:7826-34
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013;31:4305-13
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Courbron D, Hamer M, et al. Rapid manufacture and release of a GMP batch of avian influenza A (H7N9) virus-like particle vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. BioProcess J 2013;12:4-17
   Google Scholar
• A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1. Available from: http://clinicaltrials.gov/ct2/results?term=NCT01897701&Search=Search
   Google Scholar
• Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013;369:2564-6
   PubMed Web of Science ®Google Scholar
• Klausberger M, Wilde M, Palmberger D, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014;32:355-62
   PubMed Web of Science ®Google Scholar
• Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One 2012;7:e51559
   PubMed Web of Science ®Google Scholar
• Lee DH, Bae SW, Park JK, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine 2013;31:3268-73
   PubMed Web of Science ®Google Scholar
• Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011;29:5911-18
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Pearce MB, Florese R, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology 2013;442:67-73
   PubMed Web of Science ®Google Scholar
• Sun Y, Carrion R Jr, Ye L, et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009;383:12-21
   PubMed Web of Science ®Google Scholar
• Visciano ML, Diomede L, Tagliamonte M, et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine 2011;29:4903-12
   PubMed Web of Science ®Google Scholar
• El-Attar L, Oliver SL, Mackie A, et al. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 2009;27:3201-8
   PubMed Web of Science ®Google Scholar
• Azevedo MS, Gonzalez AM, Yuan L, et al. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin Vaccine Immunol 2010;17:420-8
   PubMed Web of Science ®Google Scholar
• Lu B, Huang Y, Huang L, et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 2010;130:254-61
   PubMed Web of Science ®Google Scholar
• Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors-coexpression of 3 or 4 bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res 1993;21:1219-23
   PubMed Web of Science ®Google Scholar
• Stewart M, Dubois E, Sailleau C, et al. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen. Vaccine 2013;31:553-8
   PubMed Web of Science ®Google Scholar
• Hu YC, Bentley WE, Edwards GH, et al. Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography. Biotechnol Bioeng 1999;63:721-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Parham NJ, Zhang F, et al. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 2012;30:2301-8
   PubMed Web of Science ®Google Scholar
• Koho T, Koivunen MR, Oikarinen S, et al. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antiviral Res 2014;104:93-101
   PubMed Web of Science ®Google Scholar
• Metz SW, Gardner J, Geertsema C, et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013;7:e2124
   PubMed Web of Science ®Google Scholar
• Chikungunya Virus Vaccine Trial in Healthy Adults. Available from: http://clinicaltrials.gov/ct2/results?term=NCT01489358&Search=Search
   Google Scholar
• Wagner JM, Pajerowski JD, Daniels CL, et al. Enhanced production of chikungunya virus-like particles using a high-pH adapted Spodoptera frugiperda insect cell line. PLoS One 2014;9:e94401
   PubMed Web of Science ®Google Scholar
• Basavappa R, Syed R, Flore O, et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 resolution. Protein Sci 1994;3:1651-69
   PubMed Web of Science ®Google Scholar
• Urakawa T, Ferguson M, Minor PD, et al. Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J Gen Virol 1989;70:1453-63
   PubMed Web of Science ®Google Scholar
• Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010;9:149-56
   PubMed Web of Science ®Google Scholar
• Hu YC, Hsu TA, Huang JH, et al. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 2003;25:919-25
   PubMed Web of Science ®Google Scholar
• Chung YC, Huang JH, Lai CW, et al. Expression, purification and characterization of enterovirus 71 virus-like particles. World J Gastroenterol 2006;12:921-7
   PubMed Web of Science ®Google Scholar
• Lin SY, Chung YC, Chiu HY, et al. Evaluation of the stability of enterovirus 71 virus-like particle. J Biosci Bioeng 2014;117:366-71
   PubMed Web of Science ®Google Scholar
• Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008;26:1855-62
   PubMed Web of Science ®Google Scholar
• Lin YL, Yu CI, Hu YC, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012;30:1305-12
   PubMed Web of Science ®Google Scholar
• Chung CY, Chen CY, Lin SY, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010;28:6951-7
   PubMed Web of Science ®Google Scholar
• Gong M, Zhu H, Zhou J, et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 2014;88:6444-52
   PubMed Web of Science ®Google Scholar
• Oem JK, Park JH, Lee KN, et al. Characterization of recombinant foot-and-mouth disease virus pentamer-like structures expressed by baculovirus and their use as diagnostic antigens in a blocking ELISA. Vaccine 2007;25:4112-21
   PubMed Web of Science ®Google Scholar
• Cao Y, Lu Z, Sun J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol 2009;137:10-17
   PubMed Web of Science ®Google Scholar
• Mohana Subramanian B, Madhanmohan M, Sriraman R, et al. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency. Antiviral Res 2012;96:288-95
   PubMed Web of Science ®Google Scholar
• Porta C, Kotecha A, Burman A, et al. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 2013;9:e1003255
   PubMed Web of Science ®Google Scholar
• Porta C, Xu X, Loureiro S, et al. Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. J Virol Methods 2013;187:406-12
   PubMed Web of Science ®Google Scholar
• Bhat SA, Saravanan P, Hosamani M, et al. Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge. Res Vet Sci 2013;95:1217-23
   PubMed Web of Science ®Google Scholar
• Basagoudanavar SH, Hosamani M, Tamil Selvan RP, et al. Development of a liquid-phase blocking ELISA based on foot-and-mouth disease virus empty capsid antigen for seromonitoring vaccinated animals. Arch Virol 2013;158:993-1001
   PubMed Web of Science ®Google Scholar
• Tjia ST, Altenschildesche GMZ, Doerfler W. Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells. Virology 1983;125:107-17
   PubMed Web of Science ®Google Scholar
• Volkman LE, Goldsmith PA. In vitro study of Autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl Environ Microbiol 1983;45:1085-93
   PubMed Web of Science ®Google Scholar
• Granados RR. Replication phenomena of insect viruses in vivo and in vitro. In: Miltenburger HG, editor. Safety aspects of baculoviruses as biological pesticides. Bundesministerium fur Forschung und Technologie; Bonn, Germany: 1978
   Google Scholar
• Carbonell LF, Klowden MJ, Miller LK. Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. J Virol 1985;56:153-60
   PubMed Web of Science ®Google Scholar
• Laakkonen JP, Makela AR, Kakkonen E, et al. Clathrin-independent entry of baculovirus triggers uptake of E. coli in non-phagocytic human cells. PLoS One 2009;4:e5093
   PubMed Web of Science ®Google Scholar
• Dong SC, Wang ML, Qiu ZJ, et al. Autographa californica multicapsid nucleopolyhedrovirus efficiently infects Sf9 cells and transduces mammalian cells via direct fusion with the plasma membrane at low pH. J Virol 2010;84:5351-9
   PubMed Web of Science ®Google Scholar
• Paul A, Prakash S. Baculovirus reveals a new pH-dependent direct cell-fusion pathway for cell entry and transgene delivery. Future Virol 2010;5:533-7
   Web of Science ®Google Scholar
• Makkonen KE, Turkki P, Laakkonen JP, et al. 6-O- and N-sulfated syndecan-1 promotes baculovirus binding and entry into mammalian cells. J Virol 2013;87:11148-59
   PubMed Web of Science ®Google Scholar
• Mahonen AJ, Makkonen KE, Laakkonen JP, et al. Culture medium induced vimentin reorganization associates with enhanced baculovirus-mediated gene delivery. J Biotechnol 2010;145:111-19
   PubMed Web of Science ®Google Scholar
• Turkki P, Makkonen KE, Huttunen M, et al. Cell susceptibility to baculovirus transduction and echovirus infection is modified by protein kinase C phosphorylation and vimentin organization. J Virol 2013;87:9822-35
   PubMed Web of Science ®Google Scholar
• Kukkonen SP, Airenne KJ, Marjomaki V, et al. Baculovirus capsid display: a novel tool for transduction imaging. Mol Ther 2003;8:853-62
   PubMed Web of Science ®Google Scholar
• Liu Y, Joo KI, Lei Y, Wang P. Visualization of intracellular pathways of engineered baculovirus in mammalian cells. Virus Res 2014;181:81-91
   PubMed Web of Science ®Google Scholar
• Zhang F, Zheng Z, Liu SL, et al. Self-biotinylation and site-specific double labeling of baculovirus using quantum dots for single-virus in-situ tracking. Biomaterials 2013;34:7506-18
   PubMed Web of Science ®Google Scholar
• Wen L, Lin Y, Zheng ZH, et al. Labeling the nucleocapsid of enveloped baculovirus with quantum dots for single-virus tracking. Biomaterials 2014;35:2295-301
   PubMed Web of Science ®Google Scholar
• Abe T, Matsuura Y. Host innate immune responses induced by baculovirus in mammals. Curr Gene Ther 2010;10:226-31
   PubMed Web of Science ®Google Scholar
• Abe T, Hemmi H, Miyamoto H, et al. Involvement of the toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 2005;79:2847-58
   PubMed Web of Science ®Google Scholar
• Abe T, Kaname Y, Wen X, et al. Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol 2009;83:7629-40
   PubMed Web of Science ®Google Scholar
• Chuang CK, Wong TH, Hwang SM, et al. Baculovirus transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. Mol Ther 2009;17:889-96
   PubMed Web of Science ®Google Scholar
• Chen GY, Shiah HC, Su HJ, et al. Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3 (TLR3) pathway. J Virol 2009;83:10548-56
   PubMed Web of Science ®Google Scholar
• Ono C, Ninomiya A, Yamamoto S, et al. Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells. J Virol 2014;88:2157-67
   PubMed Web of Science ®Google Scholar
• Lee HP, Matsuura Y, Chen HC, et al. Baculovirus transduction of chondrocytes elicits interferon-α/β and suppresses transgene expression. J Gene Med 2009;11:302-12
   PubMed Web of Science ®Google Scholar
• Lynch AG, Tanzer F, Fraser MJ, et al. Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production. BMC Biotechnol 2010;10:30
   PubMed Web of Science ®Google Scholar
• Quattrocchi V, Molinari P, Langellotti C, et al. Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity. Vaccine 2013;31:2713-18
   PubMed Web of Science ®Google Scholar
• Makela AR, Oker-Blom C. Baculovirus display: a multifunctional technology for gene delivery and eukaryotic library development. Adv Virus Res 2006;68:91-112
   PubMed Web of Science ®Google Scholar
• Zhou J, Blissard GW. Display of heterologous proteins on gp64null baculovirus virions and enhanced budding mediated by a vesicular stomatitis virus G-stem construct. J Virol 2008;82:1368-77
   PubMed Web of Science ®Google Scholar
• Wu QF, Fang LR, Wu XB, et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol Immunol 2009;46:2210-17
   PubMed Web of Science ®Google Scholar
• Grabowska AK, Lipinska AD, Rohde J, et al. New baculovirus recombinants expressing Pseudorabies virus (PRV) glycoproteins protect mice against lethal challenge infection. Vaccine 2009;27:3584-91
   PubMed Web of Science ®Google Scholar
• Huang H, Xiao S, Qin J, et al. Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. Arch Virol 2011;156:753-8
   PubMed Web of Science ®Google Scholar
• Li YM, Ye J, Cao SB, et al. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice. J Gene Med 2009;11:150-9
   PubMed Web of Science ®Google Scholar
• Fang R, Feng H, Nie H, et al. Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. Vaccine 2010;28:1803-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen XW, Tong TZ, et al. BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens. Vaccine 2014;32:664-70
   PubMed Web of Science ®Google Scholar
• Fan HY, Pan YF, Fang LR, et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. J Virol Methods 2008;150:21-6
   PubMed Web of Science ®Google Scholar
• Ye Y, Cheng X, Zhang J, et al. Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2. Virol J 2013;10:316
   PubMed Web of Science ®Google Scholar
• Wang SP, Fang LR, Fan HY, et al. Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 2007;25:8220-7
   PubMed Web of Science ®Google Scholar
• Wu Q, Xu F, Fang L, et al. Enhanced immunogenicity induced by an alphavirus replicon-based pseudotyped baculovirus vaccine against porcine reproductive and respiratory syndrome virus. J Virol Methods 2013;187:251-8
   PubMed Web of Science ®Google Scholar
• Lee HJ, Park N, Cho HJ, et al. Development of a novel viral DNA vaccine against human papillomavirus: acHERV-HP16L1. Vaccine 2010;28:1613-19
   PubMed Web of Science ®Google Scholar
• Cho HJ, Lee S, Im S, et al. Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus vector. Pharm Res 2012;29:585-93
   PubMed Web of Science ®Google Scholar
• Lee HJ, Hur YK, Cho YD, et al. Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One 2012;7:e50296
   PubMed Web of Science ®Google Scholar
• Cho H, Lee HJ, Heo YK, et al. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. PLoS One 2014;9:e95961
   PubMed Web of Science ®Google Scholar
• Choi JY, Gwon YD, Kim JK, et al. Protective efficacy of a human endogenous retrovirus envelope-coated. nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009. PLoS One 2013;8:e80762
   Web of Science ®Google Scholar
• Grabherr R, Ernst W, Oker-Blom C, Jones I. Developments in the use of baculoviruses for the surface display of complex eukaryotic proteins. Trends Biotechnol 2001;19:231-6
   PubMed Web of Science ®Google Scholar
• Mlambo G, Kumar N, Yoshida S. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 2010;28:7025-9
   PubMed Web of Science ®Google Scholar
• Yoshida S, Araki H, Yokomine T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun 2010;78:595-602
   PubMed Web of Science ®Google Scholar
• Yang DG, Chung YC, Lai YK, et al. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol Ther 2007;15:989-96
   PubMed Web of Science ®Google Scholar
• Tang XC, Lu HR, Ross TM. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 2010;28:6821-31
   PubMed Web of Science ®Google Scholar
• Lin YH, Lee LH, Shih WL, et al. Baculovirus surface display of sigmaC and sigmaB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. Vaccine 2008;26:6361-7
   PubMed Web of Science ®Google Scholar
• Xu XG, Chiou MT, Zhang YM, et al. Baculovirus surface display of Erns envelope glycoprotein of classical swine fever virus. J Virol Methods 2008;153:149-55
   PubMed Web of Science ®Google Scholar
• Xu XG, Liu HJ. Baculovirus surface display of E2 envelope glycoprotein of classical swine fever virus and immunogenicity of the displayed proteins in a mouse model. Vaccine 2008;26:5455-60
   PubMed Web of Science ®Google Scholar
• Xu XG, Tong DW, Chiou MT, et al. Baculovirus surface display of NS3 nonstructural protein of classical swine fever virus. J Virol Methods 2009;159:259-64
   PubMed Web of Science ®Google Scholar
• Premanand B, Kiener TK, Meng T, et al. Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res 2012;95:311-15
   PubMed Web of Science ®Google Scholar
• Xu XG, Wang ZS, Zhang Q, et al. Baculovirus surface display of E envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine 2011;29:636-43
   PubMed Web of Science ®Google Scholar
• Lin WY, Fan HY, Cheng XL, et al. A baculovirus dual expression system-based vaccine confers complete protection against lethal challenge with H9N2 avian influenza virus in mice. Virol J 2011;8:273
   PubMed Web of Science ®Google Scholar
• Chen CY, Liu HJ, Tsai CP, et al. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 2010;28:7644-51
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin SY, Cheng MC, et al. Baculovirus vector as an avian influenza vaccine: hemagglutinin expression and presentation augment the vaccine immunogenicity. J Biotechnol 2013;164:143-50
   PubMed Web of Science ®Google Scholar
• Wu Q, Yu F, Xu J, et al. Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model. Vet Microbiol 2014;171:93-101
   PubMed Web of Science ®Google Scholar
• Blagborough AM, Yoshida S, Sattabongkot J, et al. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 2010;28:6014-20
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kawasaki M, Hariguchi N, et al. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun 2009;77:1782-9
   PubMed Web of Science ®Google Scholar
• Iyori M, Nakaya H, Inagaki K, et al. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One 2013;8:e70819
   PubMed Web of Science ®Google Scholar
• Syed Musthaq S, Madhan S, Hameed AS, et al. Localization of VP28 on the baculovirus envelope and its immunogenicity against white spot syndrome virus in Penaeus monodon. Virology 2009;391:315-24
   PubMed Web of Science ®Google Scholar
• Colin GH, James JV, William EB. In vitro and in vivo RNA interference mediated suppression of Tn-caspase-1 for improved recombinant protein production in High FiveTM cell culture with the baculovirus expression vector system. Biotechnol Bioeng 2009;104:390-9
   PubMed Web of Science ®Google Scholar
• Karuppannan AK, Qiang J, Chang CC, et al. A novel baculovirus vector shows efficient gene delivery of modified porcine reproductive and respiratory syndrome virus antigens and elicits specific immune response. Vaccine 2013;31:5471-8
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Velumani S, He F, et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008;380:412-20
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Madhan S, Prabhu N, et al. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 2010;84:3201-9
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Madhan S, Prabhu N, et al. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res 2010;86:180-7
   PubMed Web of Science ®Google Scholar
• Prabakaran M, He F, Meng T, et al. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 2010;84:11822-30
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Kolpe AB, He F, et al. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine 2013;31:1385-92
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Meng T, He F, et al. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 influenza A virus induces protective immunity in mice. Clin Vaccine Immunol 2011;18:1582-5
   PubMed Web of Science ®Google Scholar
• Rajesh Kumar S, Syed Khader SM, Kiener TK, et al. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus. PLoS One 2013;8:e63856
   PubMed Web of Science ®Google Scholar
• Meng T, Kolpe AB, Kiener TK, et al. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 2011;6:e21757
   PubMed Web of Science ®Google Scholar
• Premanand B, Prabakaran M, Kiener TK, et al. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS One 2013;8:e55536
   PubMed Web of Science ®Google Scholar
• Marek M, van Oers MM, Devaraj FF, et al. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol Bioeng 2011;108:1056-67
   PubMed Web of Science ®Google Scholar
• Mehrabadi M, Hussain M, Asgari S. MicroRNAome of Spodoptera frugiperda cells (Sf9) and its alteration following baculovirus infection. J Gen Virol 2013;94:1385-97
   PubMed Web of Science ®Google Scholar
• Chen CY, Wu HH, Chen CP, et al. Biosafety assessment of human mesenchymal stem cells engineered by hybrid baculovirus vectors. Mol Pharm 2011;8:1505-14
   PubMed Web of Science ®Google Scholar
• Chen GY, Hwang SM, Su HJ, et al. Defective antiviral responses of induced pluripotent stem cells to viral vector transduction. J Virol 2012;86:8041-9
   PubMed Web of Science ®Google Scholar
• Chuang CK, Lin KJ, Lin CY, et al. Xenotransplantation of human mesenchymal stem cells into immunocompetent rats for calvarial bone repair. Tissue Eng Part A 2010;16:479-88
   PubMed Web of Science ®Google Scholar
• Hofmann C, Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther 1998;5:531-6
   PubMed Web of Science ®Google Scholar
• Kaikkonen MU, Ylä-Herttuala S, Airenne KJ. How to avoid complement attack in baculovirus-mediated gene delivery. J Invertebr Pathol 2011;107:S71-9
   PubMed Web of Science ®Google Scholar
• Kaikkonen MU, Maatta AI, Yla-Herttuala S, et al. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. Mol Ther 2010;18:987-92
   PubMed Web of Science ®Google Scholar
• Kaname Y, Tani H, Kataoka C, et al. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64. J Virol 2010;84:3210-19
   PubMed Web of Science ®Google Scholar
• Yang Y, Lo SL, Yang JY, et al. Polyethylenimine coating to produce serum-resistant baculoviral vectors for in vivo gene delivery. Biomaterials 2009;30:5767-74
   PubMed Web of Science ®Google Scholar
• Yang J, Balasundaram G, Lo SL, et al. Microfibers fabricated by non-covalent assembly of peptide and DNA for viral vector encapsulation and cancer therapy. Adv Mater 2012;24:3280-4
   PubMed Web of Science ®Google Scholar
• Paul A, Binsalamah ZM, Khan AA, et al. A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials 2011;32:8304-18
   PubMed Web of Science ®Google Scholar
• Paul A, Shao W, Abbasi S, et al. PAMAM dendrimer-baculovirus nanocomplex for microencapsulated adipose stem cell-gene therapy: in vitro and in vivo functional assessment. Mol Pharm 2012;9(9):2479-88
   PubMed Web of Science ®Google Scholar
• Stewart M, Bhatia Y, Athmaran TN, et al. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Vaccine 2010;28:3047-54
   PubMed Web of Science ®Google Scholar
• Stewart M, Dovas CI, Chatzinasiou E, et al. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012;30:2131-9
   PubMed Web of Science ®Google Scholar
• Wen Z, Ye L, Gao Y, et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 2009;84:215-24
   PubMed Web of Science ®Google Scholar
• Krammer F, Nakowitsch S, Messner P, et al. Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol J 2010;5:17-23
   PubMed Web of Science ®Google Scholar
• Krammer F, Schinko T, Palmberger D, et al. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 2010;45:226-34
   PubMed Web of Science ®Google Scholar
• Haynes JR, Dokken L, Wiley JA, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009;27:530-41
   PubMed Web of Science ®Google Scholar
• Kang SM, Yoo DG, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009;4:e4667
   PubMed Web of Science ®Google Scholar
• Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine 2011;29:4003-7
   PubMed Web of Science ®Google Scholar
• Argilaguet JM, Perez-Martin E, Lopez S, et al. BacMam immunization partially protects pigs against sublethal challenge with African swine fever virus. Antiviral Res 2013;98:61-5
   PubMed Web of Science ®Google Scholar
• Cao Y, Lu Z, Sun P, et al. A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice. Virol J 2011;8:77
   PubMed Web of Science ®Google Scholar
• Fang R, Feng H, Hu M, et al. Evaluation of immune responses induced by SAG1 and MIC3 vaccine cocktails against Toxoplasma gondii. Vet Parasitol 2012;187:140-6
   PubMed Web of Science ®Google Scholar
• Zhu B, Ye J, Lu P, et al. Induction of antigen-specific immune responses in mice by recombinant baculovirus expressing premembrane and envelope proteins of West Nile virus. Virol J 2012;9:132
   PubMed Web of Science ®Google Scholar
• Yoshida S, Nagumo H, Yokomine T, et al. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines. PLoS One 2010;5:e13727
   PubMed Web of Science ®Google Scholar
• Xu XG, Wang ZS, Zhang Q, et al. Baculovirus as a PRRSV and PCV2 bivalent vaccine vector: baculovirus virions displaying simultaneously GP5 glycoprotein of PRRSV and capsid protein of PCV2. J Virol Methods 2012;179:359-66
   PubMed Web of Science ®Google Scholar
• Li M, Wang YF, Wang Y, et al. Immune responses induced by a BacMam virus expressing the E2 protein of classical swine fever virus in mice. Immunol Lett 2009;125:145-50
   PubMed Web of Science ®Google Scholar
• Kolpe AB, Kiener TK, Grotenbreg GM, et al. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 2012;168:64-72
   PubMed Web of Science ®Google Scholar
• Syed MS, Kwang J. Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against White Spot Syndrome Virus in Penaeus monodon. PLoS One 2011;6:e26428
   PubMed Web of Science ®Google Scholar